Developing multi-antigen vaccine for the treatment of chronic HBV

Ended Project Grant Awarded Last action

Award ID
R44DK113858
Recipient
Awarding agency
Obligated
$8,209,350

Award facts

Assistance listing
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
Completion date
Originally
Funding
  • $7,269,655.00 Federal
  • $939,695.00 Non-federal
Place of performance
Farmington, CT 06032, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment -$29 $0
Amendment $1,140,300 $0
Amendment $954,675 $0
Amendment $954,675 $0
Amendment $954,675 $0
Amendment $939,695 $0
Amendment GMP manufacture of clinical grade therapeutic vaccine for the treatment of patients with chronic HBV - the ultimate objective of this sbir project is to develop… $939,695 $939,695
Amendment $1,710 $0
Amendment $768,496 $0
Original award $615,763 $0

Quick answers

Who received award R44DK113858?

R44DK113858 was awarded to Carogen Corp by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on June 5, 2018.

How much is award R44DK113858 worth?

$8,209,350 has been obligated on R44DK113858: $7,269,655 in federal funding and $939,695 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award